Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Nuvalent

Request full access

Targeted small-molecule cancer therapies for kinase-driven cancers

Cambridge, United StatesFounded 2017Biotech & Life Sciences

About Nuvalent

Nuvalent is a biotechnology company focused on developing targeted therapies for cancer patients. The company specializes in creating innovative small molecules that precisely inhibit kinase targets, which are proteins involved in the growth and spread of cancer cells. Nuvalent's primary focus is on non-small cell lung cancer (NSCLC) with ROS1 positive and ALK positive mutations, but it also has multiple discovery-stage research programs in progress.

Nuvalent operates in the oncology market, serving patients who have not responded well to existing treatments. The company partners with healthcare providers to identify patient needs and the limitations of current therapies. By leveraging its deep expertise in chemistry and structure-based drug discovery, Nuvalent aims to overcome the dual challenges of resistance and selectivity in cancer treatment.

The business model is centered around research and development, with revenue generated through the commercialization of its therapies, either independently or through partnerships with larger pharmaceutical companies.

Source: Dealroom company data

At a glance

Status
Listed
Listing
IPO 2021

Nuvalent in the Cambridge ecosystem

Live from Dealroom

The Nuvalent office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

24 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A12 investors entered at this stage

Series B and later12 investors entered at this stage

Team profiled 7 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 4 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Patents

Estimated portfolio value
$1M

11 active patent families included in this estimate.

A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.

Explore the patent portfolioPatent records, technology areas and peer comparisonsBook a demo

See Nuvalent on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.